Research programme: anti-viral therapeutics - TGV Laboratories

Drug Profile

Research programme: anti-viral therapeutics - TGV Laboratories

Alternative Names: MV-4; T-169

Latest Information Update: 11 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TGV-Laboratories
  • Class Antivirals; Small molecules
  • Mechanism of Action Glycoprotein modulators; Phospholipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV-1 infections; HIV-2 infections
  • Research Adenovirus infections; Influenza virus infections; Poliomyelitis

Most Recent Events

  • 11 May 2018 Preclinical development for HIV-1 infections and HIV-2 infections is ongoing in Russia (TGV-Labs pipeline, May 2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-1-infections in Russia (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-2-infections in Russia (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top